Profound Medical Corp. (PRN.TO)
CAD 10.21
(-0.68%)
CAD 10.21
(-0.68%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -22.29 Million | -25.8 Million | -22.36 Million | -20.57 Million | -15.33 Million | -13.43 Million |
| Net Income | -28.56 Million | -28.66 Million | -30.69 Million | -21.62 Million | -15.45 Million | -15.24 Million |
| Depreciation & Amortization | 1.14 Million | 1.6 Million | 1.87 Million | 1.53 Million | 1.54 Million | 1.22 Million |
| Deferred income taxes | 232 Thousand | - | -293 Thousand | 237 Thousand | 119.85 Thousand | -70.93 Thousand |
| Stock-based compensation | 3.41 Million | 4.23 Million | 7.2 Million | 3.01 Million | 1.28 Million | 797.48 Thousand |
| Change in working capital | 374 Thousand | -5.62 Million | -877 Thousand | -4.63 Million | -3.73 Million | -990.83 Thousand |
| Other non-cash items | 1.1 Million | 2.65 Million | 425 Thousand | 890 Thousand | 914.04 Thousand | 847.17 Thousand |
| Investing Cash Flow | - | - | -593 Thousand | -350 Thousand | -191.38 Thousand | - |
| Investments in PPE | - | - | -593 Thousand | -350 Thousand | -191.38 Thousand | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | -709.4 Thousand | -445.34 Thousand | -245.41 Thousand | - |
| Financing Cash Flow | 1.46 Million | 7.03 Million | 5.94 Million | 87.43 Million | 6.74 Million | 27.81 Million |
| Debt repayment | -1.2 Million | -356 Thousand | -386 Thousand | -9.6 Million | -1.26 Million | -4.29 Million |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 3.6 Million | 342.38 Thousand | 8.06 Million | 85.52 Million | 8.8 Million | 25.32 Million |
| Other Financing Activities | 2.66 Million | 7.38 Million | 6.33 Million | 11.51 Million | -791.97 Thousand | 6.77 Million |
| Accounts receivables | -1.41 Million | -1.92 Million | 1.99 Million | -4.02 Million | -1.05 Million | 1.14 Million |
| Accounts payables | 1.35 Million | -566 Thousand | -356 Thousand | 102 Thousand | -18.49 Thousand | -857.05 Thousand |
| Inventory | 353 Thousand | -1.86 Million | -2.49 Million | -2.14 Million | -867.22 Thousand | -1.61 Million |
| Other working capital | 78 Thousand | -1.27 Million | -26 Thousand | 1.43 Million | -1.79 Million | 332.38 Thousand |
| Cash at beginning of period | 46.51 Million | 67.15 Million | 83.91 Million | 14.8 Million | 23.49 Million | 8.15 Million |
| Cash at end of period | 26.21 Million | 46.51 Million | 67.15 Million | 83.91 Million | 14.71 Million | 22.53 Million |
| Capital Expenditure | - | - | -593 Thousand | -350 Thousand | -191.38 Thousand | - |
| Effect of forex changes on cash | 529 Thousand | -1.86 Million | 244 Thousand | 2.6 Million | 0.77 | - |
| Net cash flow / Change in cash | -20.3 Million | -20.63 Million | -16.76 Million | 69.11 Million | -8.77 Million | 14.37 Million |
| Free Cash Flow | -22.29 Million | -25.8 Million | -22.95 Million | -20.92 Million | -15.52 Million | -13.43 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -6.91 Million | -6.19 Million | -8.9 Million | -28.56 Million | -5.56 Million | -7.35 Million |
| Depreciation & Amortization | 287 Thousand | 305 Thousand | 299 Thousand | 1.14 Million | 287 Thousand | 277 Thousand |
| Deferred income taxes | - | - | - | 232 Thousand | - | 353 Thousand |
| Stock-based compensation | 768 Thousand | 767 Thousand | 907 Thousand | 3.41 Million | 727 Thousand | 842 Thousand |
| Change in working capital | -674 Thousand | 28 Thousand | 209 Thousand | 374 Thousand | 33 Thousand | 682 Thousand |
| Other non-cash items | 188 Thousand | 1000.00 | 477 Thousand | 1.1 Million | 179 Thousand | 82 Thousand |
| Investing Cash Flow | - | - | - | - | - | 239 Thousand |
| Investments in PPE | - | - | - | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | -675 Thousand | 20.38 Million | -491 Thousand | 1.46 Million | -189 Thousand | -239 Thousand |
| Debt repayment | -676 Thousand | -696 Thousand | -495 Thousand | -1.2 Million | -191 Thousand | -239 Thousand |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | 22.93 Million | 12.82 Thousand | 3.6 Million | 289.89 | 310.62 Thousand |
| Other Financing Activities | 1000.00 | -1.85 Million | 4000.00 | 2.66 Million | 2000.00 | 239 Thousand |
| Accounts receivables | -841 Thousand | 1.15 Million | -1.87 Million | -1.41 Million | 10 Thousand | 642 Thousand |
| Accounts payables | 62 Thousand | -570 Thousand | 1.19 Million | 1.35 Million | -169 Thousand | 355 Thousand |
| Inventory | 12 Thousand | -180 Thousand | 407 Thousand | 353 Thousand | 137 Thousand | 139 Thousand |
| Other working capital | -202 Thousand | -642 Thousand | 488 Thousand | 78 Thousand | 55 Thousand | -454 Thousand |
| Cash at beginning of period | 41.18 Million | 26.21 Million | 33.62 Million | 46.51 Million | 39.27 Million | 42.98 Million |
| Cash at end of period | 34.07 Million | 41.18 Million | 26.21 Million | 26.21 Million | 33.62 Million | 39.27 Million |
| Capital Expenditure | - | - | - | - | - | - |
| Effect of forex changes on cash | -76 Thousand | -318 Thousand | 96 Thousand | 529 Thousand | -1.12 Million | 1.41 Million |
| Net cash flow / Change in cash | -7.1 Million | 14.96 Million | -7.41 Million | -20.3 Million | -5.65 Million | -3.7 Million |
| Free Cash Flow | -6.35 Million | -5.09 Million | -7.01 Million | -22.29 Million | -4.33 Million | -5.11 Million |
7360
603421
HBIO
PERI
CYC
BAC-PM